231 related articles for article (PubMed ID: 30538135)
1.
Martín-Garcia D; Navarro A; Valdés-Mas R; Clot G; Gutiérrez-Abril J; Prieto M; Ribera-Cortada I; Woroniecka R; Rymkiewicz G; Bens S; de Leval L; Rosenwald A; Ferry JA; Hsi ED; Fu K; Delabie J; Weisenburger D; de Jong D; Climent F; O'Connor SJ; Swerdlow SH; Torrents D; Beltran S; Espinet B; González-Farré B; Veloza L; Costa D; Matutes E; Siebert R; Ott G; Quintanilla-Martinez L; Jaffe ES; López-Otín C; Salaverria I; Puente XS; Campo E; Beà S
Blood; 2019 Feb; 133(9):940-951. PubMed ID: 30538135
[TBL] [Abstract][Full Text] [Related]
2. Leukemic non-nodal cyclin D1- and SOX11-negative mantle cell lymphoma with CCND3::IGH rearrangement.
Tan L; Bansal G; Yeung CC; Yin J; Dave BJ; Konnick E; Wu D; Naresh KN
Ann Hematol; 2024 Feb; 103(2):667-669. PubMed ID: 37882866
[No Abstract] [Full Text] [Related]
3. A Cyclin D1-Dependent Transcriptional Program Predicts Clinical Outcome in Mantle Cell Lymphoma.
Demajo S; Albero R; Clot G; Castellano G; Navarro A; Capdevila C; Enjuanes A; Nadeu F; Giné E; Pinyol M; Jaffe ES; Ott G; Staudt LM; Rosenwald A; Scott DW; Rimsza LM; López-Guillermo A; Beà S; Campo E; Jares P
Clin Cancer Res; 2021 Jan; 27(1):213-225. PubMed ID: 33046520
[TBL] [Abstract][Full Text] [Related]
4. Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes.
Nadeu F; Martin-Garcia D; Clot G; Díaz-Navarro A; Duran-Ferrer M; Navarro A; Vilarrasa-Blasi R; Kulis M; Royo R; Gutiérrez-Abril J; Valdés-Mas R; López C; Chapaprieta V; Puiggros M; Castellano G; Costa D; Aymerich M; Jares P; Espinet B; Muntañola A; Ribera-Cortada I; Siebert R; Colomer D; Torrents D; Gine E; López-Guillermo A; Küppers R; Martin-Subero JI; Puente XS; Beà S; Campo E
Blood; 2020 Sep; 136(12):1419-1432. PubMed ID: 32584970
[TBL] [Abstract][Full Text] [Related]
5. Proapoptotic protein BIM as a novel prognostic marker in mantle cell lymphoma.
Wang JD; Katz SG; Morgan EA; Yang DT; Pan X; Xu ML
Hum Pathol; 2019 Nov; 93():54-64. PubMed ID: 31425695
[TBL] [Abstract][Full Text] [Related]
6. The positive nuclear staining observed with monoclonal antibody against PRAD1/cyclin D1 correlates with mRNA expression in mantle cell lymphoma.
Kuroda H; Komatsu H; Nakamura S; Niitsu Y; Takahashi T; Ueda R; Seto M
Jpn J Cancer Res; 1995 Sep; 86(9):890-8. PubMed ID: 7591969
[TBL] [Abstract][Full Text] [Related]
7. Large B-cell lymphoma with IRF4 rearrangement: a multi-centric study with focus on potential misleading phenotypes.
Pizzi M; Bongiovanni L; Lorenzi L; Righi S; Scarmozzino F; Balzarini P; Santoro L; Mussolin L; Carraro E; Pillon M; Bonaldi L; Vianello F; Agostinelli C; Ponzoni M; Dei Tos AP; Sabattini E
Virchows Arch; 2024 Mar; 484(3):521-526. PubMed ID: 37962684
[TBL] [Abstract][Full Text] [Related]
8. Mantle Cell Lymphoma Under the Scope of Personalized Medicine: Perspective and Directions.
Gallucci Figorelle L; Galvão PT; de Lima FMR; Marimon P; Pentagna N; Milito C; Schaffel R; Carneiro K
Clin Lymphoma Myeloma Leuk; 2024 Mar; ():. PubMed ID: 38641485
[TBL] [Abstract][Full Text] [Related]
9. Development of a murine model for blastoid variant mantle-cell lymphoma.
Ford RJ; Shen L; Lin-Lee YC; Pham LV; Multani A; Zhou HJ; Tamayo AT; Zhang C; Hawthorn L; Cowell JK; Ambrus JL
Blood; 2007 Jun; 109(11):4899-906. PubMed ID: 17311992
[TBL] [Abstract][Full Text] [Related]
10. SOX11/PRDX2 axis modulates redox homeostasis and chemoresistance in aggressive mantle cell lymphoma.
De Bolòs A; Sureda-Gómez M; Carreras-Caballé M; Rodríguez ML; Clot G; Beà S; Giné E; Campo E; Balsas P; Amador V
Sci Rep; 2024 Apr; 14(1):7863. PubMed ID: 38570586
[TBL] [Abstract][Full Text] [Related]
11. Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival.
Wiestner A; Tehrani M; Chiorazzi M; Wright G; Gibellini F; Nakayama K; Liu H; Rosenwald A; Muller-Hermelink HK; Ott G; Chan WC; Greiner TC; Weisenburger DD; Vose J; Armitage JO; Gascoyne RD; Connors JM; Campo E; Montserrat E; Bosch F; Smeland EB; Kvaloy S; Holte H; Delabie J; Fisher RI; Grogan TM; Miller TP; Wilson WH; Jaffe ES; Staudt LM
Blood; 2007 Jun; 109(11):4599-606. PubMed ID: 17299095
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for etiology and prognosis of mantle cell lymphoma.
Wang Y; Ma S
Expert Rev Hematol; 2014 Apr; 7(2):233-43. PubMed ID: 24559208
[TBL] [Abstract][Full Text] [Related]
13. A Pancreatic Collision Tumor Comprising Mantle Cell Lymphoma and Adenocarcinoma: A Case Report and Literature Review.
Sugaya R; Taniguchi A; Abe M; Ozawa I; Kirito K; Hatakeyama S
Intern Med; 2024 Feb; 63(4):553-558. PubMed ID: 37380453
[TBL] [Abstract][Full Text] [Related]
14. A peculiar case of cyclin D1-positive lymphoplasmacytic lymphoma.
Luu BE; Xu SA
Blood; 2023 Dec; 142(23):2034. PubMed ID: 38060270
[No Abstract] [Full Text] [Related]
15. Unraveling MCL biology to understand resistance and identify vulnerabilities.
Sarkozy C; Tessoulin B; Chiron D
Blood; 2024 Mar; ():. PubMed ID: 38551811
[TBL] [Abstract][Full Text] [Related]
16. The mutational landscape of Burkitt-like lymphoma with 11q aberration is distinct from that of Burkitt lymphoma.
Wagener R; Seufert J; Raimondi F; Bens S; Kleinheinz K; Nagel I; Altmüller J; Thiele H; Hübschmann D; Kohler CW; Nürnberg P; Au-Yeung R; Burkhardt B; Horn H; Leoncini L; Jaffe ES; Ott G; Rymkiewicz G; Schlesner M; Russell RB; Klapper W; Siebert R
Blood; 2019 Feb; 133(9):962-966. PubMed ID: 30567752
[TBL] [Abstract][Full Text] [Related]
17. Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma.
Grommes C; Tang SS; Wolfe J; Kaley TJ; Daras M; Pentsova EI; Piotrowski AF; Stone J; Lin A; Nolan CP; Manne M; Codega P; Campos C; Viale A; Thomas AA; Berger MF; Hatzoglou V; Reiner AS; Panageas KS; DeAngelis LM; Mellinghoff IK
Blood; 2019 Jan; 133(5):436-445. PubMed ID: 30567753
[TBL] [Abstract][Full Text] [Related]
18. Gray-zone Lymphoma Between cHL and Large B-Cell Lymphoma: A Histopathologic Series From the LYSA.
Sarkozy C; Copie-Bergman C; Damotte D; Ben-Neriah S; Burroni B; Cornillon J; Lemal R; Golfier C; Fabiani B; Chassagne-Clément C; Parrens M; Herbaux C; Xerri L; Bossard C; Laurent C; Cheminant M; Cartron G; Cabecadas J; Molina T; Salles G; Steidl C; Ghesquières H; Mottok A; Traverse-Glehen A
Am J Surg Pathol; 2019 Mar; 43(3):341-351. PubMed ID: 30540571
[TBL] [Abstract][Full Text] [Related]
19. Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group.
Redondo AM; Valcárcel D; González-Rodríguez AP; Suárez-Lledó M; Bello JL; Canales M; Gayoso J; Colorado M; Jarque I; Del Campo R; Arranz R; Terol MJ; Rifón JJ; Rodríguez MJ; Ramírez MJ; Castro N; Sánchez A; López-Jiménez J; Montes-Moreno S; Briones J; López A; Palomera L; López-Guillermo A; Caballero D; Martín A;
Br J Haematol; 2019 Mar; 184(5):797-807. PubMed ID: 30548583
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
